



Guidance For Services In Grampian To Supply Naloxone To People At Risk Of Opioid Overdose, Significant Others And Services In Contact With Those At Risk

Co-ordinators: Specialist Pharmacists in Substance Use and Medicines Management	Consultation Group: See page 10	Approver: Medicine Guidelines and Policies Group
---	---	--

Signature: 		Signature: 
---	--	---

Identifier: MGPG/Guide/NaloxoneS/1484	Review Date: February 2027	Date Approved: February 2024
---	--------------------------------------	--

Uncontrolled when printed
Version 3

Executive Sign-Off

This document has been endorsed by the Director of Pharmacy and Medicines Management

Signature:  _____

Title: Guidance For Services In Grampian To Supply Naloxone To People At Risk Of Opioid Overdose, Significant Others And Services In Contact With Those At Risk

Unique Identifier: MGPG/Guide/NaloxoneS/1484

Replaces: NHSG/Guide/NaloxoneS/MGPG1085, Version 2.1

Across NHS Boards	Organisation Wide	Directorate	Clinical Service	Sub Department Area

This controlled document shall not be copied in part or whole without the express permission of the author or the author's representative.

Lead Author/Co-ordinator: Specialist Pharmacists in Substance Use and Medicines Management

Subject (as per document registration categories): Service Guidance

Key word(s): Naloxone, guidance, framework, supply, opioid, opiate, overdose, drug, treatment, services

Process Document: Policy, Protocol, Procedure or Guideline Guidance

Document application: NHS Grampian

Purpose/description: To provide guidance, ensure clinical governance and maintain consistency of service in making supply of naloxone to the key groups in lieu of amendment to the Human Medicines (Amendment no.3) Regulations (2015).

Responsibilities for implementation:

Organisational: Chief Executive and Management Teams
Corporate: Senior Managers
Departmental: Heads of Service/Clinical Leads
Area: Line Managers
Hospital/Interface services: Assistant General Managers and Group Clinical Directors
Operational Management Unit: Unit Operational Managers
Policy statement: It is the responsibility of all staff to ensure that they are working to the most up to date and relevant policies, protocols procedures.

Review: This policy will be reviewed in three years or sooner if current treatment recommendations change.

Responsibilities for review of this document: Specialist Pharmacists in Substance Use and Medicines Management

Responsibilities for ensuring registration of this document on the NHS Grampian Information/Document Silo: Pharmacy and Medicines Directorate

Physical location of the original of this document: Fulton Clinic, Royal Cornhill Hospital, Aberdeen

Job/group title of those who have control over this document: Specialist Pharmacists in Substance Use and Medicines Management

Responsibilities for disseminating document as per distribution list: Specialist Pharmacists in Substance Use and Medicines Management

Revision History:

Revision Date	Previous Revision Date	Summary of Changes (Descriptive summary of the changes made)	Changes Marked* (Identify page numbers and section heading)
July 2023	April 2020	Simplified wording around legislation in introduction.	Page 2, Section 1.
July 2023	April 2020	Removed maximum of 2 kits per supply – there may be circumstances where more are appropriate.	Page 8, Section 5.4
July 2023	April 2020	Amended to enable direct entry of data into neo360.	Page 9, Section 5.7
July 2023	April 2020	Amended useful resources links.	Page 10, Section 6
Dec 2023	April 2020	Added information around Crown Office and Procurator Fiscal Service statement of prosecution.	Page 2, Section 1
Dec 2023	April 2020	Added information regarding supply by services not classified as drug treatment.	Page 4, Section 1.4
Dec 2023	April 2020	Simplified first bullet to clarify that those who cannot receive supply.	Page 5, Section 1.7
Dec 2023	April 2020	Added naloxone 1.26mg nasal spray.	Throughout document
Dec 2023	April 2020	Checked and updated statistics and links throughout document.	Throughout document
Dec 2023	April 2020	Rechecked amendments from July 2023 to ensure they remain valid.	Throughout document
Dec 2023	April 2020	Checked and updated references.	Throughout document
Dec 2023	April 2020	Simplified Key Information Sheet.	Appendix 1
Dec 2023	April 2020	Added MHRA recommendations on opioid risk of dependence and addiction.	Page 3, Section 1.3.

Revision Date	Previous Revision Date	Summary of Changes (Descriptive summary of the changes made)	Changes Marked* (Identify page numbers and section heading)
Dec 2023	April 2020	Added link to Live Well With Pain thermometer to replace Appendix 1.	Page 3, Section 1.3 and Appendices
Dec 2023	April 2020	Added information on community pharmacy emergency naloxone service and associated link to TURAS.	Page 5, Section 3.
Jan 2024	April 2020	Added recommended refresher period of 3 years to ensure knowledge remains current.	Page 5, Section 3.
Jan 2024	April 2020	Reworded comment on use of needles by people who inject drugs.	Page 6, Section 5.1
Jan 2024	April 2020	Importance of calling an ambulance added to section.	Page 9, Section 5.6.
March 2024	April 2020	Updated consultation comments. Material change expressing lack of absolute contraindications to supply or use.	Page 5, Section 1.7

* Changes marked should detail the section(s) of the document that have been amended, i.e. page number and section heading.

Guidance For Services In Grampian To Supply Naloxone To People At Risk Of Opioid Overdose, Significant Others And Services In Contact With Those At Risk

Contents	Page No
1. Introduction	2
1.1 Objectives	2
1.2 Definitions	3
1.3 Who is at Risk of, or Might Witness, an Opioid Overdose.....	3
1.4 People Who Can Make A Supply Of Naloxone Under This Guidance	4
1.5 People Who Can Receive A Supply Of Naloxone Under This Guidance	4
1.6 Guidance On Supply To Children And Young People	4
1.7 People Who Cannot Receive A Supply of Naloxone Under This Guidance.....	5
2. Evidence Base.....	5
3. Training and Competence Of People Making Supplies of Naloxone	5
4. What to Cover with People Receiving the Naloxone Supply (People At Risk, Significant Others, Services In Contact With Those At Risk)	6
5. Naloxone Supply Information	6
5.1 Choice of Product	6
5.2 Prenoxad® Intra-muscular Injection.....	7
5.2.1 Dosage and Administration Information - Prenoxad®.....	7
5.3 Naloxone Nasal Sprays	7
5.3.1 Dosage and Administration Information for Naloxone Nasal Sprays	8
5.4 Number of supplies	8
5.5 Contraindications To The Use Of Naloxone.....	9
5.6 Managing Symptoms Of Opioid Withdrawal	9
5.7 Data Recording And Monitoring.....	9
5.8 Stock Management.....	9
6. Useful Resources	10
7. Consultation.....	10
8. Distribution List	11
9. References	11
Appendix 1 - Grampian Take Home Naloxone Key Points Sheet	13
Appendix 2 - Grampian Naloxone Take Home Programme - Declaration of Competence.....	14
Appendix 3 - Grampian Naloxone Take Home Program - Record of Training and Supply	16
Appendix 4 - Getting Started As a Naloxone Supplier.....	18
Appendix 5 - Be Prepared For An Opioid Emergency	20

Guidance For Services In Grampian To Supply Naloxone To People At Risk Of Opioid Overdose, Significant Others And Services In Contact With Those At Risk

1. Introduction

Scotland continues to experience significant numbers of drug related deaths ¹. Over the past 5 years one or more opioids (including heroin/morphine and methadone) were either implicated or potentially contributed to death in an average of 86% of cases. If naloxone had been used, some of these deaths may have been prevented.

Legislation exists which means that naloxone can be administered by anyone for the purpose of saving a life. This enabled introduction of the Naloxone Take Home Programme (Scotland) which allows supply to, and administration of naloxone by, those people who are likely to encounter opioid overdose.

A change in legislation² in 2015 allowed the supply of naloxone without the need for a prescription, patient group direction (PGD) or patient specific direction (PSD). Information on this change can be found in the joint Department of Health, Medicines and Healthcare Products Regulatory Agency (MHRA) and Public Health England Guidance "[Widening the availability of naloxone](#)". In Scotland the Lord Advocate provided a Statement of Prosecution which further widened the services eligible to make a supply beyond drug treatment services⁴. This remains in place at time of writing and means that any service in Scotland can make supplies of naloxone with appropriate training and registration.

This document ensures that a clear framework of governance remains in place for services delivering naloxone supplies in Grampian. It refers to the supply and use of naloxone in the event of a suspected opioid overdose in community settings.

1.1 Objectives

To increase access to naloxone supply and overdose awareness training (in a bid to reduce the number of deaths associated with opioid overdose) by:

- Widening the range of services and professionals (clinical and non-clinical) eligible to undertake naloxone supply.
- Educating patients around risks from opioids both prescribed, e.g. analgesics, methadone, buprenorphine and illicit.
- Removing barriers to significant others and services in contact with people at risk of opioid overdose receiving a naloxone supply.
- Providing a governance framework for services involved in the supply of naloxone in the absence of a PGD or PSD.

Note: This guidance does not prevent the supply of naloxone nasal spray or intramuscular injection (Prenoxad[®]) by prescription.

1.2 Definitions

Naloxone: A drug which can temporarily reverse the effects of opioid drugs such as heroin, buprenorphine, morphine, codeine and methadone in overdose situations.

Naloxone Take Home Programme (Scotland): Scottish Government supported initiative making naloxone kits available to people at risk of, or most likely to witness an opioid overdose in a bid to reduce drug related death. It includes components of training on overdose awareness and naloxone administration and where this fits when giving basic life support.

Drug treatment services: For this purpose drug treatment services are provided by, on behalf of, or under arrangements made by an NHS body, local authority or Public Health Agency. In Grampian, authorisation to supply naloxone through non-clinical services will be agreed with the commissioning organisation. Injecting Equipment Providers (IEPs) and Community Pharmacies which dispense Opioid Replacement Therapy are automatically included under this definition.

1.3 Who is at Risk of, or Might Witness, an Opioid Overdose

- People who use prescription opioids, in particular those taking higher doses.
- People who use any type of opioid in combination with other sedating substances such as benzodiazepines or alcohol.
- People who use any type of opioid and have medical conditions such as HIV, liver, lung disease or who suffer from depression.
- People with opioid dependence, in particular following reduced tolerance (following detoxification, release from prison, breaks in or stopping treatment).
- People who inject opioids.
- Anyone in contact with people who use opioids (in all categories above).

Risk Associated with Opioid Analgesia

Opioid overdose may be a risk for people taking opioid analgesia^{5, 6} for any indication (including pain or opioid dependence and/or addiction).

Recommendations were published by the MHRA in 2020 including which can be accessed here: www.gov.uk/drug-safety-update/opioids-risk-of-dependence-and-addiction

They include a useful patient information leaflet to aid discussion:

<https://assets.publishing.service.gov.uk/media/5f6a078ed3bf7f7238f23100/Opioid-patient-safety-information-leaflet-v2-Aug2021.pdf>

Opioid related overdose risk is dose-dependent⁷

- Dosages of between 50 and 100mg oral morphine equivalent dose per day (MED/d) increases the risk for opioid overdose by factors of 1.9 to 4.6 compared with dosages of up to 20mg MED/d.
- Dosages of 100mg or more MED/d increases the risk of overdose significantly - by factors of 2.0 to 8.9 compared dosages of up to 20mg MED/d.

“Live Well With Pain” has a useful visual thermometer to help discuss these risks. <https://livewellwithpain.co.uk/wp-content/uploads/2022/09/Thermometers-2023.pdf>

In primary care the Scottish Therapeutics Utility (STU) tool may help identify people at higher risk of opioid overdose through the “Chronic pain report” as this highlights patients currently prescribed high dose morphine or equivalent doses of opioids.

1.4 People Who Can Make A Supply Of Naloxone Under This Guidance

Any member of staff from a participating service, who has completed the necessary training who can demonstrate the necessary competencies (see [Section 3](#) and [Appendix 2](#)). They can be clinical or non-clinical and includes suitably trained and supported volunteers. This includes any trained member of community pharmacy staff (i.e. it does not have to be a pharmacist). Services which are not classified as drug treatment services must be registered with the Scottish Government through the local naloxone lead.

Note: NHS staff who are not part of a drug treatment service can still use this guidance to identify patients at risk of an opioid overdose and cover the key points. The only difference is that the supply of naloxone will need to be made either by issuing a prescription, recommendation of a prescription or direct supply via a PGD.

1.5 People Who Can Receive A Supply Of Naloxone Under This Guidance

- People at risk of opioid overdose (from any type of opioid, prescribed or illicit).
- People who are likely to witness opioid overdose, e.g. carers, family members, partners, friends.
- Organisations and businesses likely to be in contact with people at risk of opioid overdose (non-clinical settings), e.g. hostels, homeless shelters, etc.

Before making a supply of naloxone the person receiving the supply must be able to demonstrate a basic awareness of opioid overdose, basic life support and naloxone use.

1.6 Guidance On Supply To Children And Young People

Overdose awareness training and supply of naloxone to children and young people is not a decision that should be made in isolation. It will form part of the wider considerations of child welfare and protection that fit with existing child protection guidelines ([National Guidance for Child Protection in Scotland 2021 – updated 2023](#)) to ensure that children and young people are safe and protected from harm. Practitioners should ensure that a referral is made to Children and Families Social Work if that has not already been done to allow assessment of the needs and risk for the child. Each case should be considered using [GIRFEC principles](#) using the [National Practice Model](#) and [National Risk Assessment Framework](#) in a multi-agency context to assess need and risk.

It is essential that the multi-agency “Team around the Child” is involved in the planning and decision making when considering whether to include the child in this aspect of their parents/carers management of overdose. The Child’s Plan should include this aspect of the plan. Where a child or young person is in a position where they could witness or experience opioid overdose and where the environment has been assessed as safe for the child to remain, training and/or supply of naloxone may be appropriate. The staff member should assess whether the child has sufficient ability and understanding to be trained to:

- Contact emergency services by dialling 999 and asking for an ambulance.
- Administer naloxone (nasal product should be supplied).
- Undertake Basic Life Support.
- Watch for a response and decide on further action needed whilst waiting for emergency services.

Training should be tailored according to capacity. For example it may be that a child can understand when and how to contact an ambulance but would not be able to administer basic life support or administer naloxone.

1.7 People Who Cannot Receive A Supply of Naloxone Under This Guidance

There are no absolute contraindications to supply or use of naloxone, the product is for use in life-threatening emergencies. Further discussion may be required in the following circumstances to determine whether supply is appropriate.

- People who are unable to demonstrate a basic understanding of naloxone use.
- People who are deemed as having insufficient capacity to agree to receive, or who has not provided consent to receive, a supply of naloxone.
- Where a person expresses a known allergy to naloxone.

2. Evidence Base

The supply of naloxone as described forms a key component of national and international policies aimed at reducing the incidence of drug related deaths. It is included in guidance documentation from the World Health Organisation⁸, Advisory Council on the Misuse of Drugs, MHRA, Department of Health and Public Health England³. The supply forms part of a national programme introduced and evaluated by the Scottish Government⁹.

3. Training and Competence Of People Making Supplies of Naloxone

The service or line manager is responsible for ensuring that people making naloxone supply have access to training and are competent. As a minimum requirement before undertaking supply of naloxone staff should:

- Complete the [SDF e-learning package](#) or complete a recognised Naloxone Take Home Programme training event. Pharmacy staff should complete the pharmacy specific TURAS modules <https://learn.nes.nhs.scot/70968> (see below)
- Read and understand this guidance document.

- Watch the videos on the administration of naloxone products available for supply www.prenoxadinjection.com/video/admin.mp4, www.nyxoid.com/uk and <https://naloxone.uk/>

Community Pharmacy Staff

All community pharmacies in Scotland should now hold a supply of naloxone for use in emergency situations in the vicinity of the pharmacy. Pharmacy specific naloxone eLearning was created to support this which mirrors the SDF training but is available on TURAS. Modules can be accessed here: <https://learn.nes.nhs.scot/70968>
Once completed the person should be able to:

- Answer questions relating to overdose awareness and naloxone supply and administration.
- Know where to refer to for further professional advice or support if required.

The line manager should ensure that all staff are updated on any changes to this guidance and should retain a record of staff trained and eligible to make a supply of naloxone. The competency checklist ([Appendix 2](#)) can be used to support this.

It is recommended that eLearning is completed a minimum of every 3 years to ensure staff remain up to date but can be completed earlier to refresh knowledge.

4. What to Cover with People Receiving the Naloxone Supply (People At Risk, Significant Others, Services In Contact With Those At Risk)

The information outlined in NHS Grampian's "Naloxone Key points Summary" ([Appendix 1](#)) should be covered to assure that people receiving a supply of naloxone have sufficient knowledge on when and how to use it.

5. Naloxone Supply Information

5.1 Choice of Product

Naloxone is available as two options in Grampian, intramuscular injection (must be Prenoxad[®] brand) and nasal spray formulations (generic product and Nyxoid[®]). An up to date list of current naloxone products can be found in the [Grampian Area Formulary](#). Administration of a single dose of any formulation is expected to produce similar initial results when following recommended instructions. People should be offered a supply of the product they feel is most appropriate.

Prenoxad[®] intramuscular injection may be more appropriate for people who:

- State that they have a preference for Prenoxad[®].
- Have been supplied with and/or used the injectable format before and who are familiar and confident with its use.

A nasal spray may be more appropriate:

- For people who state a preference for this formulation.

- For people who do not feel comfortable administering the injectable product, e.g. family members, non-clinical service workers, people who do not inject the opioid.
- For younger people, e.g. children living with parents at risk of opioid overdose.
- Where needles are not suited to the environment or accommodation, e.g. in prison wings or hostel accommodation.
- Where company policy does not support staff administration of injectable products.

Note: People who inject substances may utilise the needles for other purposes which may cause issues if overdose occurs and the Prenoxad® no longer has its needles. Ensure the person knows where their nearest Injecting Equipment Provider is, encourage uptake of sufficient needles and consider whether a nasal naloxone kit may be a better option.

5.2 Prenoxad® Intra-muscular Injection

Prenoxad® (naloxone hydrochloride 2mg/2mL pre-filled syringe for injection) is the only **injectable** naloxone product which is suitable for supply under this guidance. The pack contains a pre-filled syringe, a patient information leaflet and two needles. The second needle is included as a back-up should the first one become damaged. It is not necessary to change needles between injections unless the needle becomes damaged. The kit is packaged within a hard shell case which should be used to contain and dispose of the syringe and needles following use. Other versions of naloxone do not contain any needles or the appropriate information leaflet and would be unable to be used in an emergency in non-clinical settings.

5.2.1 Dosage and Administration Information - Prenoxad®

One dose (400micrograms in 0.4mL) of naloxone should be injected into the outer thigh muscle or upper arm muscle. The syringe contains five doses which are clearly marked. If there is no response after 2-3 minutes a further dose should be administered. This should be repeated until either:

- The person regains consciousness **or**
- All 5 doses have been used (further doses may be given if available) **or**
- The emergency services arrive and take over.

More information, including a video, can be found on the Prenoxad® website www.prenoxadinjection.com.

5.3 Naloxone Nasal Sprays

There are two formulations of naloxone approved for use, Nyxoid® (naloxone hydrochloride dihydrate 1.8mg per nasal spray) and a generic preparation (naloxone hydrochloride dihydrate 1.26mg per nasal spray). Both product packs contain two individual single dose nasal spray devices and a patient information leaflet. Nyxoid® contains a slightly higher dose however both have proven effective in reversing opioid overdose.

Due to its higher dose, Nyxoid® should be the preferred option if comparing the two. The more compact design of the naloxone 1.26mg nasal spray may be attractive to some and make it easier to carry. It can therefore be offered to people who state a preference for it and who may otherwise refuse naloxone supply.

Nyxoid® nasal spray is the only product licensed from 14 years so is the preferred product for younger people at risk (age 14 to 18 years).

5.3.1 Dosage and Administration Information for Naloxone Nasal Sprays

- The nasal spray **should not** be primed or tested prior to use as it only contains a single dose of naloxone.
- The contents of a single nasal spray should be sprayed into the casualty's nostril.
- If there is no response after 2-3 minutes a second nasal spray should be sprayed, ideally into the other nostril.
- If the patient does not respond to two doses, further doses may be given (if available).

Videos and resources, for each product can be accessed using the following links:

- Naloxone 1.26mg nasal spray: <https://naloxone.uk/>
- Nyxoid® nasal spray: <https://nyxoid.com/uk>.

5.4 Number of supplies

People at risk of, or likely to witness, a future opioid overdose can receive:

- One Prenoxad® kit or one pack of naloxone nasal spray.
- Additional Prenoxad® kits or packs of naloxone nasal spray to hold as a spare supply if required appropriate to their need, e.g. if someone splits time between family home and other properties.
- Two different formats may be supplied in one transaction, i.e. a combination of naloxone nasal spray and Prenoxad®.

Services in contact with those at risk of future opioid overdose may also be provided with an appropriate number of kits for the size and activity of the service. Care Inspectorate Guidance should be followed¹⁰. It is the responsibility of the service receiving the supply to ensure that they have processes and protocols in place which meet its recommendations.

Practical information that should be discussed when making a naloxone supply include:

- It is not necessary to keep Prenoxad® or naloxone nasal spray in a fridge.
- The pack should remain sealed until needed. It provides reassurance to the person administering the kit that it contains the stated dose(s) of naloxone.
- Where to access further training and resupplies of lost, used or expired kits (see list of participating services).
- Used or expired kits can be returned to any community pharmacy for disposal.

- The relevant Prenoxad® “Assembly and Administration Guide” or patient information leaflet for naloxone nasal spray should be given with each supply (orderable from NHS Grampian Health Information Resources Service). Leaflets can also be printed from the following links:
 - Nyxoid® www.medicines.org.uk/emc/rmm/1278/Document
 - Naloxone 1.26mg nasal spray <https://naloxone.uk/guidance-for-uk-healthcare-professionals-and-drug-service-workers/>
 - Prenoxad® www.medicines.org.uk/emc/product/3054/rmms

5.5 Contraindications To The Use Of Naloxone

There are no exclusions from administering naloxone where opioid overdose is suspected, as not administering may result in the death of the person.

5.6 Managing Symptoms Of Opioid Withdrawal

The most common side effect of naloxone is opioid withdrawal. In a person who is physically dependent on opioids this is often likened to severe influenza. Symptoms may include but are not limited to: body aches, diarrhoea, rapid heart rate, fever, runny nose, sneezing, sweating, yawning, nausea, vomiting, restlessness, irritability, shivering, trembling, abdominal cramps and weakness.

People receiving a supply of naloxone should be informed that symptoms of withdrawal can be experienced when administering naloxone but they will generally be short lived. If faced with an overdose situation the casualty should be reassured that the effects of naloxone will begin to wear off after 20-30 minutes and **strongly advised against** the use of additional substances. The importance of calling an ambulance to assess and support the casualty should be reinforced. Further substance use will significantly increase the risk of further overdose.

5.7 Data Recording And Monitoring

Data can either be entered directly into the approved data collection system (currently neo360®) or by completing the Grampian “Record of Naloxone Training, Supply and Resupply” ([Appendix 3](#)) and subsequently entering into neo360®. The consent of the person receiving naloxone should be gained both for recording details of supplies made and sharing this data anonymously for the purposes of project monitoring.

The line manager is responsible for ensuring confidentiality of the records.

Data recording is not required where naloxone supply is made using a prescription. Prescribing data can be automatically monitored using existing processes.

5.8 Stock Management

Services should ensure that they have adequate protocols in place for the ordering, monthly date checking, rotation and disposal of stock. Services may be requested to produce protocols and demonstrate compliance to commissioners and/or the local naloxone lead. Products have a relatively short expiry date of 3 years from date of manufacture. To maximise the effective lifespan of stock, no more than one month's

supply of naloxone should be kept in hand at any one time and stock ordered frequently. Clinical services should order and manage stocks of naloxone in line with other medications. Non-clinical services should contact NHS Grampian's naloxone co-ordinator for advice on stock ordering and management.
Email: gram.smspharmacists@nhs.scot for advice.

6. Useful Resources

Links, information and videos are available on the Grampian hi-net website: www.hi-netgrampian.scot.nhs.uk/naloxone/

- Community Pharmacy specific information can be accessed on the NHS Scotland Community Pharmacy website: www.communitypharmacy.scot.nhs.uk/nhs-boards/nhs-grampian
- Public facing "Grampian overdose" page: www.nhsgrampian.org/naloxone
- Scottish Drugs Forum national website: www.stopthedeaths.com/
- The International Overdose Awareness Day website also contains useful fact sheets and resources: www.overdoseday.com/
- Prenoxad® "How to" Videos: www.prenoxadinjection.com/hcp/how-to.html
- Prenoxad® and Opioid Overdose: www.prenoxadinjection.com/hcp/abt_naloxone.html
- When/how to give Prenoxad®: www.prenoxadinjection.com/hcp/when_and_how.html
- Naloxone 1.26mg nasal spray: <https://naloxone.uk/>
- Nyxoid® Video: www.nyxoid.com/uk

7. Consultation

Dr Steve Beason	Psychiatrist, Timmermarket Clinic
Linda Buchan	Nurse Team Lead, Kittybrewster Police Custody
Dr Carol Buchanan	GP With Special Interest, Aberdeen City
Rhona Campbell	Nurse Team Lead, Timmermarket Clinic
Tia Chidothe	Nurse Manager Aberdeenshire Drug and Alcohol Service
Dr Roberto Cotroneo	Consultant Psychiatrist and Clinical Lead, NHS Grampian Drug and Alcohol Services
Alana Gibbs	Advanced Pharmacist, Aberdeenshire Drug and Alcohol Service
Anne Marshall	Community Pharmacist, Wills Chemists, Inverurie
Andrew McKechnie	Advanced Pharmacist, Aberdeenshire Drug and Alcohol Services
Fiona Miele	Lead Child Protection Nurse, NHS Grampian
Elaine Neil	Lead Pharmacist, Aberdeenshire HSCP and Grampian Custodial Settings
Gillian Maclean	Direct Access Manager, Alcohol and Drugs Action
Angela MacManus	Principal Pharmacist Mental Health & Learning Disability Services
Liz Robertson	Lead Pharmacist, Aberdeen City HSCP
Naomi Scott	Consultant in Anaesthesia and Pain Medicine, ARI
Lucy Simpson	Early Intervention and Community Empowerment, Aberdeen City Council

8. Distribution List

Aberdeen City, Aberdeenshire and Moray Alcohol and Drug Partnerships
NHS Grampian Mental Health Services
NHS Grampian Acute Services
Primary Care Contracts Team (Community Pharmacies and GP Surgeries)

9. References

1. National Records Scotland (NRS), 2023. Drug Related Deaths in Scotland in 2022 Edinburgh: NRS [online]. Available from: www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-in-scotland
2. Home Office, 2015. *The Human Medicines (Amendment) (No. 3) Regulations 2015*. S.I. Medicines. 2015/1503 [online]. Available from: <http://www.legislation.gov.uk/ukxi/2015/1503/made> [Accessed 08/12/2023]
3. Department of Health, Medicines and Healthcare Products Regulatory Agency (MHRA) and Public Health England, 2016. *Widening the availability of naloxone*. (Updated 2019) [online] Available from: www.gov.uk/government/publications/widening-the-availability-of-naloxone/widening-the-availability-of-naloxone [Accessed 08/12/2023]
4. X Crown Office and Procurator Fiscal Service (COPFS), 2020. Lord Advocate's guidelines in relation to the supply of naloxone during the COVID-19/Coronavirus pandemic [online]. COPFS. Available from: www.copfs.gov.uk/publications/lord-advocate-s-guidelines-supply-of-naloxone-during-covid-19-pandemic/html/ [Accessed 08/12/2023]
5. Chou R et al, 2014. The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain. Agency for Healthcare Research and Quality (US). [Online]. Available from: www.ncbi.nlm.nih.gov/books/NBK258809/ [Accessed 08/12/2023]
6. Coe, M., Walsh, S., 2015. Distribution of Naloxone for Overdose Prevention to Chronic Pain Patients. *Preventative Medicine* (80) p. 41-43. Available from www.ncbi.nlm.nih.gov/pmc/articles/PMC4592383/ [Accessed 08/12/2023]
7. WSCCG Medicines Management Team and West Suffolk Integrated Pain Management Service, 2018. *How much opioid is the person taking? A valuable guide to dosing based on oral morphine equivalent dose/day to enable safe prescribing*. Available from: <https://livewellwithpain.co.uk> [Accessed 08/12/2023]
8. World Health Organisation (WHO), 2014. *Community management of opioid overdose*. Switzerland: WHO. Available from: http://apps.who.int/iris/bitstream/10665/137462/1/9789241548816_eng.pdf?ua=1&ua=1 [Accessed 08/12/2023]

9. Scottish Government, 2023. *National Guidance for Child Protection in Scotland 2021-Updated 2023*. Available from: <https://www.gov.scot/binaries/content/documents/govscot/publications/advice-and-guidance/2023/08/national-guidance-child-protection-scotland-2021-updated-2023/documents/national-guidance-child-protection-scotland-2021-updated-2023/national-guidance-child-protection-scotland-2021-updated-2023/govscot%3Adocument/national-guidance-child-protection-scotland-2021-updated-2023.pdf> [Accessed 08/12/2023]
10. Scottish Government, 2012. National Risk Framework to Support the Assessment of Children and Young People 2012 [online]. Available from: www.gov.scot/binaries/content/documents/govscot/publications/advice-and-guidance/2012/11/national-risk-framework-support-assessment-children-young-people/documents/national-risk-framework-support-assessment-children-young-people-2012/national-risk-framework-support-assessment-children-young-people-2012/govscot%3Adocument/00408604.pdf [Accessed 08/12/2023]
11. Watt, G., Jaquet, S., Ellison, S., Christie, I., Nicholson, J., *Service Evaluation Of Scotland's National Take-Home Naloxone Programme*. London: Crown Publishers. Available from: www.gov.scot/Resource/0045/00451251.pdf [Accessed 08/12/2023]
12. Care Inspectorate, 2016. *Health Guidance: Take Home Naloxone in Social Care Services*. Available from: www.careinspectorate.com/images/documents/3203/Take%20Home%20Naloxone%20in%20Social%20Care%20Services.pdf [Accessed 08/12/2023]
13. The British Medical Association and the Royal Pharmaceutical Society of Great Britain. *The British National Formulary*. [online] London: BMJ Group/RPS Publishing. [Accessed 14/01/2020]
14. The Electronic Medicines Compendium (eMC). Prenoxad 1mg/mL Injection - Summary Of Product Characteristics (SPC). Available from: www.medicines.org.uk. [Accessed 08/12/2023].
15. The Electronic Medicines Compendium (eMC). Nyxoid® 1.8mg nasal spray, solution in a single-dose container - Summary Of Product Characteristics (SPC). Available from: www.medicines.org.uk. [Accessed 08/12/2023].
16. Accord healthcare, 2023. Naloxone 1.26mg nasal spray. Summary of Product Characteristics [online]. Accord UK. Available from: www.accord-healthcare-products.co.uk/products/n/naloxone [Accessed 08/12/2023]

Appendix 1 - Grampian Take Home Naloxone Key Points Sheet

Be Prepared For An Opioid Emergency

KNOW THE SIGNS OF OPIOID OVERDOSE

- **UNCONSCIOUS OR NOT RESPONDING:** Not waking up or responding to voice commands or touch. Shake shoulders. Speak clearly in both ears
- **APPEARANCE:** Blue/grey skin and lips. Clammy. Very small/pinpoint pupils
- **BREATH:** Very slow or irregular breathing or no breathing at all. May also be a rasping or snoring sound

KNOW HOW TO RESPOND

- Call 999 and ask for an **AMBULANCE** - give location
- Let them know that the person is:
 - **"UNCONSCIOUS BUT BREATHING"** - Put them into recovery position
 - **"UNCONSCIOUS AND NOT BREATHING"** - Start CPR
- Administer Naloxone
- Stay with the person
- Bust myths - **DO NOT** walk person around, put in shower/bath, slap etc

KNOWS HOW NALOXONE WORKS

- Reverses the effects of opioid drugs but starts to wear off after 20 to 30 minutes
- Only works on opioid drugs (safe to use even if unsure what has been taken)
- Give a dose every 2-3 minutes until either: -
 - Person comes round **OR** Emergency services arrive and take over **OR** there is no naloxone left

CHOOSE PRODUCT TO SUPPLY. USE PRODUCT LEAFLET TO GO OVER ITS USE

HOW TO USE PRENOXAD® INJECTION

- Keep sealed until ready to use
- Twist cap off syringe and twist on needle
- Inject into outer thigh or upper arm muscle
- Give one dose at a time. Repeat every 2 to 3 minutes if no response
- Place in yellow box between injections and after used (sharps bin)

HOW TO USE NALOXONE NASAL SPRAY

- **DO NOT TEST THE SPRAY FIRST – THERE IS ONLY ONE SPRAY IN EACH NASAL SPRAY (2 sprays per pack)**
- Tilt head back
- Put the nasal spray into the nostril and press plunger
- If no response after 2 to 3 minutes give another dose in the other nostril
- Note: There are 2 brands of nasal spray, "naloxone nasal spray 1.26mg" and "Nyxoid® nasal spray". Nyxoid® is slightly stronger

IF YOU HAVE TO USE A KIT OR IT IS OUT OF DATE – REMEMBER TO GET ANOTHER ONE

Appendix 2 - Grampian Naloxone Take Home Programme - Declaration of Competence

DECLARATION OF COMPETENCE

NAME:	
SERVICE DETAILS/ADDRESS:	
EMAIL / PHONE NUMBER:	

I confirm that I:

- have completed the Scottish Drugs Forum e-learning module – “[Overdose Prevention, Intervention and Naloxone](#)” (TURAS modules for pharmacy staff) and watched the manufacturer videos for the use of [Prenoxad®](#) and [Nyxoid®](#) **OR** completed a recognised Naloxone Take Home Programme training event
- have read and understand the Grampian Guidance For Services To Supply Naloxone To People At Risk Of Opioid Overdose, Significant Others And Services In Contact With Those At Risk
- have demonstrated competence as per the Naloxone competence checklist
- have been shown which records need to be completed and the process for inputting data into neo360 (whether self or administrator). Note: recording on neo360 is not required for naloxone supplied by prescription
- would like to distribute naloxone to people who are at risk of witnessing or experiencing an overdose

Signature:	
Date:	

- Please tick this box if you consent to the local Health and Social Care Partnership keeping a record of your contact information as a naloxone supplier and providing you with information about developments and further training opportunities related to preventing drug overdoses

NAME OF PERSON CONFIRMING COMPETENCE:	
NAME OF SERVICE:	
CONTACT DETAILS:	

COMPETENCY CHECKLIST

The person should be able to explain in simple terms:
- The most common substances which increase the risk of overdose and drug related death
- The range of things which can increase the risk of overdose
- The main body system affected by overdose
- The main signs and symptoms of opioid overdose
- The correct course of action to take if faced with a suspected overdose
- How to call an ambulance, why this is important and what to say when calling
- Who needs a supply of naloxone
- Who can naloxone be administered to
- How to assemble Prenoxad®
- How to administer Prenoxad® <ul style="list-style-type: none"> - when the person is unconscious and breathing - when the person is unconscious and not breathing
- How to administer naloxone nasal spray e.g. Nyxoid®: <ul style="list-style-type: none"> - when the person is unconscious and breathing - when the person is unconscious and not breathing
- Where and how naloxone is stored and how to find the batch number and expiry date
- How to order naloxone or who to tell if naloxone stocks are low
- The service's process for staff/volunteer administration of naloxone in the event of an opioid overdose happening in or near to the service premises
- Is aware of local drug treatment services are and can help people access them
- Is aware of other key support and recovery services and can help people access them

Appendix 3 - Grampian Naloxone Take Home Program - Record of Training and Supply

TRAINING (Naloxone key points sheet COVERED WITH PERSON)

Name of Service:

Staff Member Name:

Person at risk Family Member/Friend Service Worker

M F Trainee Name:

CHI/Date of Birth: Unit Number (SMS only).....

Address:

..... Postcode:

Prison Release date (prison only):

Training checklist completed Training Declined Give Reason.....

NALOXONE® SUPPLY

Kit 1: Prenoxad® Nyxoid® Naloxone Nasal Spray 1.26mg

Batch no.: Expiry Date:

Spare: Prenoxad® Nyxoid® Naloxone Nasal Spray 1.26mg

Batch no.: Expiry Date:

1st supply Spare supply Used on self
(complete 2nd page) Used on other
(complete 2nd page)

Expired Confiscated Damaged Lost Not known

Or declined supply of naloxone State Reason

I consent to: Details of this training/supply being recorded on the electronic database
Anonymous sharing of data with the NHS for purpose of reporting and research

Signed (trainee):

Signed (staff): Date:

NALOXONE RESUPPLY – Where the naloxone kit has been used on somebody

When did the overdose occur? (Approximate date):.....

Who administered the naloxone?

- Self Paramedic Another person Unknown

Where did the overdose occur?

- My own home Somebody else's home Another indoor location
 Outdoors Other (state).....

What was the outcome?

- Opioid reversed, person went to hospital
 Opioid reversed, person did **not** go to hospital
 Person did not survive
 Not known

Additional Information:

Appendix 4 - Getting Started As a Naloxone Supplier

Who will deliver naloxone?

- Consider contact your team or service has with people at risk of or likely to experience opioid overdose
- **Identify** members of staff to train
- Have a **range of staff trained** - staff don't need to have a clinical background
- Think about coverage across the service's opening hours to ensure naloxone is easily available
- Ideally people at risk or likely to witness an overdose will leave with a supply in hand

Knowledge and training

- **Essential:** Complete SDF elearning module "Overdose Prevention, Intervention and naloxone" www.sdftraining.org.uk/e-learning
- **Essential:** Read/ensure understanding of Grampian Naloxone Guidance document + Key Information Checklist
- **Essential:** Watch video. www.nyxoid.com/uk and www.prenoxadinjection.com/hcp/how-to.html
- **If required:** Undertake face to face training.
- Have a system for recording staff trained and competent (see competency checklist)

Ready to go? **COMMUNITY PHARMACY**

- Read and sign up to the naloxone SLA
- Contact SUS pharmacists to get set up to record supplies on neo360 gram.smspharmacists@nhs.scot
- Order supplies of naloxone through usual wholesaler (naloxone nasal spray e.g. Nyxoid® and Prenoxad®). Only order what you need to keep expiry dates as long as possible.

Ready to go?

CLINICAL DRUG TREATMENT SERVICES

- Liaise with pharmacy to get Prenoxad® and nasal spray e.g. Nyxoid® added to drug ordering profile
- Order supplies of both products. Only order what you need
- Agree a system for storing, date checking and rotating stock
- Contact gram.smspharmacists@nhs.scot to get set up to record supplies on neo360 database
- Agree process for recording supplies

Ready to go?

NON- CLINICAL SERVICES

- Incorporate naloxone into service protocols as per Care Inspectorate guidance
- Contact gram.smspharmacists@nhs.scot to get set up for
 - ordering naloxone
 - recording supplies on neo360 database
- Order supplies of both products. Only order what you need
- Agree a system for storing, date checking and rotating stock

Ready to go?

GP SURGERIES

- Options for training and naloxone supply
 - 1. Cover key information and issue prescription
 - 2. Prescribe naloxone: community pharmacy providing ORT will cover key information and supply
 - 3. Hold stock onsite and make supply from surgery - any trained member of staff can do this
- Regardless of route confirm patient has supply at next visit

Ready to go?

OTHER HOSPITAL/ OUTPATIENT SERVICES

- Options for training
 - 1. Cover key information and issue prescription/add to discharge medication
 - 2. Utilise PGD and add naloxone to ward profile/order stock for supply from ward/clinic
 - 3. Refer patient to other available options above (may be less likely to result in the person getting a supply than options 1. and 2.)

Substance Use Service (SUS) Pharmacists:

Email: gram.smspharmacists@nhs.scot

Grampian Take Home Naloxone Page: www.hi-netgrampian.scot.nhs.uk/naloxone/

Appendix 5 - Be Prepared For An Opioid Emergency

Frequently Asked Questions

What are opioids?

Opioids are a group of drugs that range from mild analgesics such as “over the counter” combined codeine preparations that can be bought from community pharmacies to illegal drugs like heroin.

Prescribed opioids are most commonly used for pain relief and include but not limited to codeine, tramadol, morphine, oxycodone, dihydrocodeine, fentanyl, tapentadol and others.

Methadone and Buprenorphine are opioids generally used as part of treatment for substance use disorder or opioid dependence.

How do opioids work and what are the risks?

Opioids work on the brain. They tell it to send signals that block pain, slow breathing, and calm the body down.

People taking opioids can be unaware of the potential adverse reactions (also known as side effects). At lower doses, opioids can make people feel sleepy, but higher doses of the drugs can slow breathing and heart rate, which can lead to death.

Opioid overdose emergencies can occur even when opioids are used as instructed but especially at higher doses and when taken with other sedating substances.

What happens if all doses of naloxone have been used before help has arrived?

Keep going with basic life support until an ambulance arrives or until casualty regains consciousness.

Can naloxone be used on a child?

If a child is suspected of consuming an opioid drug 999 should be called immediately and the advice given by the call handlers followed. Nyxoid® nasal spray can be used on people aged 14 years and above. (Note: naloxone 1.26mg nasal spray is licensed in adults)

Do I need to give mouth to mouth?

The person will be lacking oxygen therefore it is recommended that two rescue breaths are given as part of each Basic Life Support cycle. If an individual cannot give rescue breaths then performing chest compressions alone are still better than doing nothing.

For Prenoxad® Intramuscular Injection Only

What happens if more than one dose is given at a time?

When naloxone is administered to an opioid dependent individual it is likely that they will experience a degree of withdrawal. If more than one dose is given at a time, the symptoms of withdrawal may be greater or last longer and may result in the person experiencing a more severe withdrawal reaction. The person in withdrawal should be reassured that the effects of naloxone will start to wear off quite quickly and strongly advised against further use as this is likely to result in a further overdose.

What happens if the needle breaks off or is damaged?

If the needle has broken off and is stuck in the person do not try to remove it. Inform the paramedics of this when they arrive. Try not to roll the person onto this side if putting into the recovery position to prevent it from being pushed in further. If it is not stuck in the person, there is a spare needle in the pack which can be used.

Can I use the same needle if more than two people have overdosed?

Coming across this scenario should be extremely rare. Ideally, a separate kit should be used for each person. Where there is only one kit available and the risk of death outweighs the risks associated with contracting a virus such as hepatitis then a dose of naloxone from the same kit could be given. There are two needles contained within each Prenoxad® kit, however there is an increased risk of needle stick injury if the needle was changed. The paramedics should be informed if the same kit has been used on multiple individuals in order that it can be followed up when the individuals are transported to the hospital.